

Ian M Anderson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8237139/publications.pdf>

Version: 2024-02-01

159
papers

12,097
citations

31902

53
h-index

27345

106
g-index

167
all docs

167
docs citations

167
times ranked

11760
citing authors

#	ARTICLE	IF	CITATIONS
1	Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. <i>Journal of Affective Disorders</i> , 2000, 58, 19-36.	2.0	845
2	Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2005, 19, 567-596.	2.0	537
3	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. <i>Journal of Psychopharmacology</i> , 2015, 29, 459-525.	2.0	528
4	Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2014, 28, 403-439.	2.0	511
5	Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis. <i>British Journal of Psychiatry</i> , 2002, 180, 396-404.	1.7	510
6	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. <i>Journal of Psychopharmacology</i> , 2008, 22, 343-396.	2.0	437
7	Magnetic resonance imaging studies in unipolar depression: Systematic review and meta-regression analyses. <i>European Neuropsychopharmacology</i> , 2012, 22, 1-16.	0.3	435
8	Systematic Review and Guide to Selection of Selective Serotonin Reuptake Inhibitors. <i>Drugs</i> , 1999, 57, 507-533.	4.9	406
9	Effects of lesions of the orbitofrontal cortex on sensitivity to delayed and probabilistic reinforcement. <i>Psychopharmacology</i> , 2002, 160, 290-298.	1.5	353
10	Meta-analytical studies on new antidepressants. <i>British Medical Bulletin</i> , 2001, 57, 161-178.	2.7	326
11	Affective Cognition and its Disruption in Mood Disorders. <i>Neuropsychopharmacology</i> , 2011, 36, 153-182.	2.8	264
12	State-dependent changes in hippocampal grey matter in depression. <i>Molecular Psychiatry</i> , 2013, 18, 1265-1272.	4.1	257
13	The Effect of Citalopram Pretreatment on Neuronal Responses to Neuropsychological Tasks in Normal Volunteers: An fMRI Study. <i>Neuropsychopharmacology</i> , 2005, 30, 1724-1734.	2.8	250
14	Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression. <i>Molecular Psychiatry</i> , 2018, 23, 133-142.	4.1	247
15	The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. <i>Journal of Psychopharmacology</i> , 1994, 8, 238-249.	2.0	244
16	The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature. <i>Journal of Affective Disorders</i> , 2019, 242, 195-210.	2.0	206
17	Bipolar disorder. <i>BMJ</i> , The, 2012, 345, e8508-e8508.	3.0	173
18	Increased Amygdala Responses to Sad But Not Fearful Faces in Major Depression: Relation to Mood State and Pharmacological Treatment. <i>American Journal of Psychiatry</i> , 2012, 169, 841-850.	4.0	163

#	ARTICLE	IF	CITATIONS
19	The effect of serotonergic and noradrenergic antidepressants on face emotion processing in depressed patients. <i>Journal of Affective Disorders</i> , 2009, 118, 87-93.	2.0	160
20	Dieting reduces plasma tryptophan and alters brain 5-HT function in women. <i>Psychological Medicine</i> , 1990, 20, 785-791.	2.7	156
21	Relationship between 5-HT function and impulsivity and aggression in male offenders with personality disorders. <i>British Journal of Psychiatry</i> , 2001, 178, 352-359.	1.7	156
22	CNR1 Gene is Associated with High Neuroticism and Low Agreeableness and Interacts with Recent Negative Life Events to Predict Current Depressive Symptoms. <i>Neuropsychopharmacology</i> , 2009, 34, 2019-2027.	2.8	153
23	The CREB1-BDNF-NTRK2 Pathway in Depression: Multiple Gene-Cognition-Environment Interactions. <i>Biological Psychiatry</i> , 2011, 69, 762-771.	0.7	142
24	Temporal discounting in major depressive disorder. <i>Psychological Medicine</i> , 2014, 44, 1825-1834.	2.7	134
25	Neurobiological substrates of antisocial and borderline personality disorder: preliminary results of a functional fMRI study. <i>Criminal Behaviour and Mental Health</i> , 2004, 14, 39-54.	0.4	131
26	ECNP consensus meeting. Bipolar depression. Nice, March 2007. <i>European Neuropsychopharmacology</i> , 2008, 18, 535-549.	0.3	131
27	Neuronal effects of acute citalopram detected by pharmacofMRI. <i>Psychopharmacology</i> , 2005, 180, 680-686.	1.5	121
28	Psychoeducation for relapse prevention in bipolar disorder: a systematic review of efficacy in randomized controlled trials. <i>Bipolar Disorders</i> , 2015, 17, 349-362.	1.1	121
29	Citalopram modulation of neuronal responses to aversive face emotions: a functional MRI study. <i>NeuroReport</i> , 2007, 18, 1351-1355.	0.6	118
30	State-dependent alteration in face emotion recognition in depression. <i>British Journal of Psychiatry</i> , 2011, 198, 302-308.	1.7	111
31	Effects of quinolinic acid-induced lesions of the orbital prefrontal cortex on inter-temporal choice: a quantitative analysis. <i>Psychopharmacology</i> , 2002, 165, 9-17.	1.5	100
32	Serotonergic modulation of neuronal responses to behavioural inhibition and reinforcing stimuli: an fMRI study in healthy volunteers. <i>European Journal of Neuroscience</i> , 2006, 23, 552-560.	1.2	99
33	Effects of orbital prefrontal cortex dopamine depletion on inter-temporal choice: a quantitative analysis. <i>Psychopharmacology</i> , 2004, 175, 206-14.	1.5	96
34	Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. <i>British Journal of Psychiatry</i> , 2000, 177, 292-302.	1.7	95
35	The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. <i>Journal of Psychopharmacology</i> , 2008, 22, 330-332.	2.0	93
36	Effect of acute tryptophan depletion on CO2-induced anxiety in patients with panic disorder and normal volunteers. <i>British Journal of Psychiatry</i> , 2000, 176, 182-188.	1.7	89

#	ARTICLE	IF	CITATIONS
37	Recognising and managing antidepressant discontinuation symptoms. <i>Advances in Psychiatric Treatment</i> , 2007, 13, 447-457.	0.6	84
38	Brain galanin system genes interact with life stresses in depression-related phenotypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E1666-73.	3.3	83
39	Quantitative frontal and temporal structural MRI studies in personality-disordered offenders and control subjects. <i>Psychiatry Research - Neuroimaging</i> , 2002, 116, 133-149.	0.9	82
40	Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial. <i>Lancet Psychiatry</i> , 2017, 4, 365-377.	3.7	82
41	Attenuated responses to emotional expressions in women with generalized anxiety disorder. <i>Psychological Medicine</i> , 2011, 41, 1009-1018.	2.7	79
42	L-Tryptophan and prolactin release: Evidence for interaction between 5-HT ₁ and 5-HT ₂ receptors. <i>Human Psychopharmacology</i> , 1986, 1, 93-97.	0.7	78
43	The effects of real versus hypothetical reward on delay and probability discounting. <i>Quarterly Journal of Experimental Psychology</i> , 2010, 63, 1072-1084.	0.6	77
44	Assessing human 5-HT function in vivo with pharmacMRI. <i>Neuropharmacology</i> , 2008, 55, 1029-1037.	2.0	75
45	Effects of quinolinic acid-induced lesions of the nucleus accumbens core on inter-temporal choice: a quantitative analysis. <i>Psychopharmacology</i> , 2007, 195, 71-84.	1.5	72
46	The Relationship between Serotonergic Function and the Psychopathy Checklist: Screening Version. <i>Journal of Psychopharmacology</i> , 2003, 17, 216-222.	2.0	70
47	Validation of the Mood Disorder Questionnaire for screening for bipolar disorder in a UK sample. <i>Journal of Affective Disorders</i> , 2008, 110, 180-184.	2.0	69
48	Effect of pindolol on endocrine and temperature responses to buspirone in healthy volunteers. <i>Psychopharmacology</i> , 1992, 106, 428-432.	1.5	68
49	The effect of orbital prefrontal cortex lesions on performance on a progressive ratio schedule: implications for models of inter-temporal choice. <i>Behavioural Brain Research</i> , 2005, 156, 145-152.	1.2	68
50	Significant association between the C(â [~] 1019)G functional polymorphism of the HTR _{1A} gene and impulsivity. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 592-599.	1.1	62
51	Clomipramine enhances prolactin and growth hormone responses to l-tryptophan. <i>Psychopharmacology</i> , 1986, 89, 131-3.	1.5	61
52	The effects of gepirone on neuroendocrine function and temperature in humans. <i>Psychopharmacology</i> , 1990, 100, 498-503.	1.5	60
53	Regional default mode network connectivity in major depressive disorder: modulation by acute intravenous citalopram. <i>Translational Psychiatry</i> , 2019, 9, 116.	2.4	59
54	Neuronal correlates and serotonergic modulation of behavioural inhibition and reward in healthy and antisocial individuals. <i>Journal of Psychiatric Research</i> , 2010, 44, 123-131.	1.5	58

#	ARTICLE	IF	CITATIONS
55	Reversed Frontotemporal Connectivity During Emotional Face Processing in Remitted Depression. <i>Biological Psychiatry</i> , 2012, 72, 604-611.	0.7	55
56	Role of the orbital prefrontal cortex in choice between delayed and uncertain reinforcers: a quantitative analysis. <i>Behavioural Processes</i> , 2003, 64, 239-250.	0.5	54
57	Variations in the cannabinoid receptor 1 gene predispose to migraine. <i>Neuroscience Letters</i> , 2009, 461, 116-120.	1.0	53
58	Diminished Neural and Cognitive Responses to Facial Expressions of Disgust in Patients with Psoriasis: A Functional Magnetic Resonance Imaging Study. <i>Journal of Investigative Dermatology</i> , 2009, 129, 2613-2619.	0.3	49
59	Effects of lesions of the nucleus accumbens core on inter-temporal choice: Further observations with an adjusting-delay procedure. <i>Behavioural Brain Research</i> , 2009, 202, 272-277.	1.2	48
60	The effect of acute citalopram on face emotion processing in remitted depression: A pharmacMRI study. <i>European Neuropsychopharmacology</i> , 2011, 21, 140-148.	0.3	47
61	Interaction between a history of depression and rumination on neural response to emotional faces. <i>Psychological Medicine</i> , 2011, 41, 1845-1855.	2.7	47
62	Social-economical decision making in current and remitted major depression. <i>Psychological Medicine</i> , 2015, 45, 1301-1313.	2.7	46
63	Executive and memory function and its relationship to trait impulsivity and aggression in personality disordered offenders. <i>Journal of Forensic Psychiatry Psychology</i> , 2002, 13, 503-526.	0.4	45
64	Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR). <i>BMJ: British Medical Journal</i> , 2018, 363, k4218.	2.4	44
65	Clinical trials of antidepressant medications are producing meaningless results. <i>British Journal of Psychiatry</i> , 2003, 183, 102-104.	1.7	43
66	Adjunctive fast repetitive transcranial magnetic stimulation in depression. <i>British Journal of Psychiatry</i> , 2007, 190, 533-534.	1.7	43
67	Decreased plasma tryptophan concentration in major depression: relationship to melancholia and weight loss. <i>Journal of Affective Disorders</i> , 1990, 20, 185-191.	2.0	42
68	d-Fenfluramine in panic disorder: a dual role for 5-hydroxytryptamine. <i>Psychopharmacology</i> , 2000, 149, 251-258.	1.5	42
69	5-HT modulation of pain perception in humans. <i>Psychopharmacology</i> , 2017, 234, 2929-2939.	1.5	40
70	Reduced Medial Prefrontal Responses to Social Interaction Images in Remitted Depression. <i>Archives of General Psychiatry</i> , 2012, 69, 37.	13.8	38
71	Neural correlates of choice behavior related to impulsivity and venturesomeness. <i>Neuropsychologia</i> , 2011, 49, 2311-2320.	0.7	37
72	Risk-Taking Behavior in a Gambling Task Associated with Variations in the Tryptophan Hydroxylase 2 Gene: Relevance to Psychiatric Disorders. <i>Neuropsychopharmacology</i> , 2010, 35, 1109-1119.	2.8	35

#	ARTICLE	IF	CITATIONS
73	Effect of acute tryptophan depletion on the response to controllable and uncontrollable noise stress. <i>Biological Psychiatry</i> , 2005, 57, 295-300.	0.7	33
74	Effect of quinolinic acid-induced lesions of the nucleus accumbens core on performance on a progressive ratio schedule of reinforcement: implications for inter-temporal choice. <i>Psychopharmacology</i> , 2008, 197, 339-350.	1.5	33
75	The HTR1A and HTR1B receptor genes influence stress-related information processing. <i>European Neuropsychopharmacology</i> , 2011, 21, 129-139.	0.3	33
76	Effect of disconnecting the orbital prefrontal cortex from the nucleus accumbens core on inter-temporal choice behaviour: A quantitative analysis. <i>Behavioural Brain Research</i> , 2008, 191, 272-279.	1.2	31
77	Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial. <i>Lancet Psychiatry</i> , 2016, 3, 117-127.	3.7	30
78	A survey of the teaching and assessment of undergraduate psychiatry in the medical schools of the United Kingdom and Ireland. <i>Medical Teacher</i> , 2009, 31, 1024-1029.	1.0	29
79	Effects of Different Stressors Are Modulated by Different Neurobiological Systems: The Role of GABA-A Versus CB1 Receptor Gene Variants in Anxiety and Depression. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 138.	1.8	29
80	Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: An open-label, pilot study. <i>Journal of Affective Disorders</i> , 2009, 117, 116-119.	2.0	28
81	Choice between reinforcer delays versus choice between reinforcer magnitudes: Differential Fos expression in the orbital prefrontal cortex and nucleus accumbens core. <i>Behavioural Brain Research</i> , 2010, 213, 269-277.	1.2	28
82	Epistatic interaction of CREB1 and KCNJ6 on rumination and negative emotionality. <i>European Neuropsychopharmacology</i> , 2011, 21, 63-70.	0.3	28
83	Variability in the Effect of 5-HTTLPR on Depression in a Large European Population: The Role of Age, Symptom Profile, Type and Intensity of Life Stressors. <i>PLoS ONE</i> , 2015, 10, e0116316.	1.1	28
84	The effect of chronic fluvoxamine on hormonal and psychological responses to buspirone in normal volunteers. <i>Psychopharmacology</i> , 1996, 128, 74-82.	1.5	27
85	Neuronal Nitric Oxide Synthase (NOS1) Polymorphisms Interact with Financial Hardship to Affect Depression Risk. <i>Neuropsychopharmacology</i> , 2014, 39, 2857-2866.	2.8	26
86	Time-dependent neuronal changes associated with craving in opioid dependence: an fMRI study. <i>Addiction Biology</i> , 2018, 23, 1168-1178.	1.4	26
87	Drug treatment of depression: reflections on the evidence. <i>Advances in Psychiatric Treatment</i> , 2003, 9, 11-20.	0.6	25
88	Detection of the acute effects of hydrocortisone in the hippocampus using pharmacological fMRI. <i>European Neuropsychopharmacology</i> , 2012, 22, 867-874.	0.3	25
89	Development and validation of the Generalized Anxiety Disorder Inventory (GADI). <i>Journal of Psychopharmacology</i> , 2007, 21, 145-152.	2.0	24
90	Rumination in migraine: Mediating effects of brooding and reflection between migraine and psychological distress. <i>Psychology and Health</i> , 2016, 31, 1481-1497.	1.2	24

#	ARTICLE	IF	CITATIONS
91	Clozapine monotherapy for catatonic schizophrenia: should clozapine be the treatment of choice, with catatonia rather than psychosis as the main therapeutic index?. <i>Journal of Psychopharmacology</i> , 2005, 19, 432-433.	2.0	23
92	Distinct effects of folate pathway genes MTHFR and MTHFD1L on ruminative response style: a potential risk mechanism for depression. <i>Translational Psychiatry</i> , 2016, 6, e745-e745.	2.4	23
93	Effect of quinolinic acid-induced lesions of the subthalamic nucleus on performance on a progressive-ratio schedule of reinforcement: A quantitative analysis. <i>Behavioural Brain Research</i> , 2008, 195, 223-230.	1.2	21
94	TOMM40 rs2075650 May Represent a New Candidate Gene for Vulnerability to Major Depressive Disorder. <i>Neuropsychopharmacology</i> , 2014, 39, 1743-1753.	2.8	21
95	Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT. <i>Health Technology Assessment</i> , 2018, 22, 1-136.	1.3	21
96	Variants in the <i>CNR1</i> gene predispose to headache with nausea in the presence of life stress. <i>Genes, Brain and Behavior</i> , 2017, 16, 384-393.	1.1	20
97	Metergoline abolishes the prolactin response to buspirone. <i>Psychopharmacology</i> , 1990, 100, 283-284.	1.5	18
98	Financial difficulties but not other types of recent negative life events show strong interactions with 5-HTTLPR genotype in the development of depressive symptoms. <i>Translational Psychiatry</i> , 2016, 6, e798-e798.	2.4	18
99	Quantitative analysis of the effect of lesions of the subthalamic nucleus on intertemporal choice: further evidence for enhancement of the incentive value of food reinforcers. <i>Behavioural Pharmacology</i> , 2009, 20, 437-446.	0.8	17
100	Managing inadequate antidepressant response in depressive illness. <i>British Medical Bulletin</i> , 2015, 115, 183-201.	2.7	17
101	Guidelines for choice of selective serotonin reuptake inhibitor in depressive illness. <i>Advances in Psychiatric Treatment</i> , 2001, 7, 170-180.	0.6	16
102	Genetic variants in the catechol-O-methyltransferase gene are associated with impulsivity and executive function: Relevance for major depression. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2012, 159B, 928-940.	1.1	16
103	Information processing in anxiety: a pilot study of the effect of manipulating 5-HT function. <i>Journal of Psychopharmacology</i> , 1998, 12, 155-160.	2.0	15
104	Changes in the neural correlates of self-blame following mindfulness-based cognitive therapy in remitted depressed participants. <i>Psychiatry Research - Neuroimaging</i> , 2020, 304, 111152.	0.9	15
105	Treatment of bipolar affective disorder in clinical practice. <i>Journal of Psychopharmacology</i> , 2001, 15, 55-57.	2.0	14
106	Enhanced subgenual cingulate response to altruistic decisions in remitted major depressive disorder. <i>NeuroImage: Clinical</i> , 2014, 4, 701-710.	1.4	14
107	A new stress sensor and risk factor for suicide: the T allele of the functional genetic variant in the CABRA6 gene. <i>Scientific Reports</i> , 2017, 7, 12887.	1.6	14
108	Associations between childhood maltreatment and inflammatory markers. <i>BJPsych Open</i> , 2019, 5, e3.	0.3	14

#	ARTICLE	IF	CITATIONS
109	Mirtazapine antagonises the subjective, hormonal and neuronal effects of m-chlorophenylpiperazine (mCPP) infusion: A pharmacological-challenge fMRI (phMRI) study. <i>NeuroImage</i> , 2011, 58, 497-507.	2.1	13
110	We all know what we mean by treatment-resistant depression – don't we?. <i>British Journal of Psychiatry</i> , 2018, 212, 259-261.	1.7	13
111	A comparison of permutation and parametric testing for between group effective connectivity differences using DCM. <i>NeuroImage</i> , 2010, 50, 509-515.	2.1	12
112	Cognitive function after electroconvulsive therapy for depression: relationship to clinical response. <i>Psychological Medicine</i> , 2021, 51, 1647-1656.	2.7	12
113	Effect of moderate weight loss on prolactin secretion in normal female volunteers. <i>Psychiatry Research</i> , 1989, 29, 161-167.	1.7	11
114	The effect of moderate weight loss on overnight growth hormone and cortisol secretion in healthy female volunteers. <i>Journal of Affective Disorders</i> , 1989, 16, 197-202.	2.0	11
115	Management of diabetes mellitus occurring during treatment with olanzapine: report of six cases and clinical implications. <i>Journal of Psychopharmacology</i> , 2004, 18, 128-132.	2.0	11
116	NewMood: A productive European model of collaboration for translational research in depression. <i>European Neuropsychopharmacology</i> , 2011, 21, 1-2.	0.3	11
117	Study protocol for the randomised controlled trial: Ketamine augmentation of ECT to improve outcomes in depression (Ketamine-ECT study). <i>BMC Psychiatry</i> , 2015, 15, 257.	1.1	11
118	CANMAT Guidelines for depression: Clear and user-friendly. <i>Journal of Affective Disorders</i> , 2009, 117, S3-S4.	2.0	10
119	Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 66.	0.7	10
120	P2RX7 gene variation mediates the effect of childhood adversity and recent stress on the severity of depressive symptoms. <i>PLoS ONE</i> , 2021, 16, e0252766.	1.1	10
121	New approaches to treating resistant depression. <i>BJ Psych Advances</i> , 2015, 21, 315-323.	0.5	9
122	Cueing emotional memories during slow wave sleep modulates next-day activity in the orbitofrontal cortex and the amygdala. <i>NeuroImage</i> , 2022, 253, 119120.	2.1	9
123	Prolactin response to the dopamine antagonist, metoclopramide, in depression. <i>Biological Psychiatry</i> , 1991, 30, 313-316.	0.7	8
124	A meta-analysis of the efficacy of selective serotonin reuptake inhibitors compared to tricyclic antidepressants in depression. <i>European Neuropsychopharmacology</i> , 1994, 4, 332.	0.3	8
125	Changes in Pharmacological treatment for Bipolar Disorder Over Time in Manchester: A Comparison with Lloyd et al. (2003). <i>Journal of Psychopharmacology</i> , 2004, 18, 441-444.	2.0	8
126	Frontal haemodynamic responses in depression and the effect of electroconvulsive therapy. <i>Journal of Psychopharmacology</i> , 2019, 33, 1003-1014.	2.0	8

#	ARTICLE	IF	CITATIONS
127	The new antidepressants. <i>Current Anaesthesia and Critical Care</i> , 1999, 10, 32-39.	0.3	7
128	Pharmacological Treatment of Unipolar Depression. <i>Current Topics in Behavioral Neurosciences</i> , 2012, 14, 263-289.	0.8	7
129	Study protocol for the randomised controlled trial: Antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study). <i>BMC Psychiatry</i> , 2013, 13, 205.	1.1	7
130	Prescribing antidepressants for depression: time to be dimensional and inclusive. <i>British Journal of General Practice</i> , 2011, 61, 50-52.	0.7	6
131	Prescribing for moderate or severe unipolar depression in patients under the long-term care of UK adult mental health services. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532093049.	1.2	6
132	Randomised controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT study). <i>Efficacy and Mechanism Evaluation</i> , 2017, 4, 1-112.	0.9	6
133	Inflamed Mind: Multiple Genetic Variants of IL6 Influence Suicide Risk Phenotypes in Interaction With Early and Recent Adversities in a Linkage Disequilibrium-Based Clumping Analysis. <i>Frontiers in Psychiatry</i> , 2021, 12, 746206.	1.3	6
134	Commentary on "Re-evaluation of the efficacy and tolerability of venlafaxine versus SSRI: meta-analysis" by Weinmann et al.. <i>Psychopharmacology</i> , 2008, 196, 521-522.	1.5	5
135	Spatiotemporal brain activation pattern following acute citalopram challenge is dose dependent and associated with neuroticism: A human pHMRI study. <i>Neuropharmacology</i> , 2020, 170, 107807.	2.0	5
136	Positive Shifts in Emotion Evaluation Following Mindfulness-Based Cognitive Therapy (MBCT) in Remitted Depressed Participants. <i>Mindfulness</i> , 2021, 12, 623-635.	1.6	5
137	Randomised controlled trial of Antiglucocorticoid augmentation (metyrapone) of anti-Depressants in Depression (ADD Study). <i>Efficacy and Mechanism Evaluation</i> , 2015, 2, 1-98.	0.9	5
138	"Out, out, brief candle! Life's but a walking shadow" 5-HTTLPR Is Associated With Current Suicidal Ideation but Not With Previous Suicide Attempts and Interacts With Recent Relationship Problems. <i>Frontiers in Psychiatry</i> , 2020, 11, 567.	1.3	4
139	Electroconvulsive therapy (ECT) versus sham ECT for depression: do study limitations invalidate the evidence (and mean we should stop using ECT)? <i>BJ Psych Advances</i> , 2021, 27, 285-291.	0.5	4
140	Commentary on STAR*D: a summary and UK perspective. <i>Journal of Psychopharmacology</i> , 2009, 23, 613-614.	2.0	2
141	Does anxiety moderate the effectiveness of mirtazapine in patients with treatment-resistant depression? A secondary analysis of the MIR trial. <i>Journal of Psychopharmacology</i> , 2020, 34, 1342-1349.	2.0	2
142	An ongoing process of reconnection: A qualitative exploration of mindfulness-based cognitive therapy for adults in remission from depression. <i>Psychology and Psychotherapy: Theory, Research and Practice</i> , 2022, 95, 173-190.	1.3	2
143	Drug Information Not Regulation is Needed. <i>Journal of Psychopharmacology</i> , 2004, 18, 14-15.	2.0	1
144	Making decisions in the absence of high quality clinical evidence: we need to bring some science into the judgement. <i>Journal of Psychopharmacology</i> , 2005, 19, 133-133.	2.0	1

#	ARTICLE	IF	CITATIONS
145	Bad medicine or bad mouthing?. BMJ: British Medical Journal, 2011, 342, d3185-d3185.	2.4	1
146	<p>Cost-effectiveness model for a hypothetical monotherapy vs standard of care in adult patients with treatment-resistant depression</p>. ClinicoEconomics and Outcomes Research, 2019, Volume 11, 257-270.	0.7	1
147	BAP depression guidelines put antidepressant treatment in context. Progress in Neurology and Psychiatry, 2008, 12, 4-5.	0.4	0
148	No medication without representation? Generalizing from antidepressant clinical efficacy trials to clinical practice. Psychological Medicine, 2011, 41, 1349-1351.	2.7	0
149	Unipolar depression and dysthymia. Medicine, 2012, 40, 591-595.	0.2	0
150	Staying well has to be the main goal. BMJ, The, 2013, 346, f2307-f2307.	3.0	0
151	Nuevos enfoques para tratar la depresi3n resistente [translation of "New approaches to treating resistant depression" by Rodolfo Zaratiegui]. BJ Psych Advances, 2015, 21, .	0.5	0
152	Unipolar depressive disorders. Medicine, 2016, 44, 654-660.	0.2	0
153	Ketamine-ECT Study " Author's reply. Lancet Psychiatry,the, 2017, 4, 662.	3.7	0
154	Does electroconvulsive therapy damage the brain?. Lancet Psychiatry,the, 2018, 5, 294-295.	3.7	0
155	Management of treatment nonresponse. , 2009, , 77-84.		0
156	Principles of therapy. , 2011, , 27-43.		0
157	Continuation and maintenance treatment. , 2011, , 85-90.		0
158	Principles of Therapy. , 2014, , 31-49.		0
159	Management of Treatment Nonresponse. , 2014, , 89-97.		0